

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background	9
2. Objective and scope	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants	12
6. Working procedures	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals	20
4. Mechanistic and other relevant data	23
5. Summary	26
6. Evaluation and rationale	27
References	31
GENERAL REMARKS	33
TOBACCO SMOKING	43
1. Exposure Data	43
1.1 Smoked tobacco products	43
1.2 Chemical composition of tobacco smoke	43
1.3 Prevalence of tobacco smoking	47
1.4 Regulations and policies: the WHO Framework Convention on Tobacco Control	56
2. Cancer in Humans	56
2.1 Introduction	56
2.2 Cancer of the lung	56
2.3 Cancers of the upper aerodigestive tract	66
2.4 Cancer of the stomach	76
2.5 Cancer of the pancreas	78

2.6	Cancer of the colorectum.....	80
2.7	Hepatocellular carcinoma	88
2.8	Renal cell carcinoma	89
2.9	Cancer of the lower urinary tract (including cancer of the bladder, ureter, and renal pelvis) .	90
2.10	Myeloid leukaemia (acute and chronic)	91
2.11	Other leukaemias and lymphomas.....	91
2.12	Cancer of the breast.....	92
2.13	Cancer of the cervix	101
2.14	Cancer of the endometrium.....	102
2.15	Cancer of the prostate	105
2.16	Cancer of the ovary.....	107
2.17	Cancer of the thyroid	108
2.18	Other cancers	108
2.19	Bidi smoking	110
2.20	Synergistic effects of tobacco smoking and alcohol drinking	114
2.21	Synthesis.....	115
3.	Cancer in Experimental Animals	120
3.1	Mainstream tobacco smoke.....	120
3.2	Co-administration of tobacco smoke with known carcinogens and other agents	121
3.3	Smoke condensates.....	129
3.4	Synthesis.....	132
4.	Other Relevant Data	132
4.1	Overview of the mechanistic evidence for the carcinogenicity of tobacco.....	132
4.2	Polymorphisms in carcinogen-metabolizing genes	146
4.3	Site-specific mechanisms of carcinogenicity of tobacco smoke	154
4.4	Mechanistic considerations of the interaction of ethanol and tobacco carcinogens.....	163
4.5	Synthesis.....	165
5.	Evaluation	167
	References	167

SECOND-HAND TOBACCO SMOKE.....213

1.	Exposure Data	213
1.1	Chemical composition.....	213
1.2	Sources of exposure.....	214
1.3	Measures of exposure.....	214
1.4	Prevalence of exposure	215
1.5	Regulations.....	226
2	Cancer in Humans.....	227
2.1	Cancer of the lung.....	227
2.2	Cancer of the breast.....	231
2.3	Cancers of the upper aerodigestive tract	235
2.4	Leukaemia and lymphomas.....	238
2.5	Other cancers in adults	238
2.6	Parental tobacco smoking and childhood cancers.....	242
2.7	Synthesis.....	251
3.	Cancer in Experimental Animals	253

3.1 Simulated second-hand tobacco smoke	253
3.2 Sidestream smoke condensate	253
3.3 Observational studies of companion animals	255
3.4 Synthesis.....	255
4. Other Relevant Data	255
5. Evaluation	255
References	255
SMOKELESS TOBACCO	265
1. Exposure Data	265
1.1 Smokeless tobacco products.....	265
1.2 Chemical composition of smokeless tobacco	265
1.3 Prevalence of use	269
2. Cancer in Humans.....	276
2.1 Oral use	276
2.2 Nasal use.....	293
2.3 Synthesis.....	294
3. Cancer in Experimental Animals	296
3.1 Chewing tobacco, unburned cigarette tobacco, <i>mishri</i> and <i>naswar</i>	296
3.2 Snuff.....	306
3.3 Synthesis.....	309
4. Other Relevant Data	309
5. Evaluation	309
References	309
N'-NITROSONORNICOTINE AND 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	319
1. Exposure Data	319
1.1. Chemical and physical data	319
1.2 Occurrence in tobacco products	320
2. Cancer in Humans.....	321
3. Cancer in Experimental Animals	322
3.1 Administration of NNN and NNK	322
3.2 NNK and NNN metabolites	327
3.3 Synthesis.....	327
4. Other Relevant Data	328
5. Evaluation	328
References	329
BETEL QUID AND ARECA NUT	333
1. Exposure Data	333
1.1 Constituents of betel quid.....	333
1.2 Prevalence of use	335
2. Cancer in Humans.....	340
2.1 Cancer of the oral cavity	340
2.2 Precancerous lesions of the oral cavity	344
2.3 Other cancers of the upper aerodigestive tract	345

2.4	Cancer of the liver	348
2.5	Other cancers	349
2.6	Synthesis	350
3.	Cancer in Experimental Animals	351
3.1	Mouse	351
3.2	Rat	358
3.3	Hamster	358
3.4	Baboon	359
3.5	Synthesis	359
4.	Other Relevant Data	360
4.1	Distribution and metabolism of the constituents of betel quid	360
4.2	Genetic and related effects	361
4.3	Mechanistic considerations	363
4.4	Synthesis	363
5	Evaluation	363
	References	364

CONSUMPTION OF ALCOHOLIC BEVERAGES.....373

1.	Exposure Data	373
1.1	Types and ethanol content of alcoholic beverages	373
1.2	Chemical composition	374
1.3	Trends in consumption of alcoholic beverages	375
2.	Cancer in Humans	376
2.1	Description of cohort studies	376
2.2.	Cancers of the upper aerodigestive tract	377
2.3	Cancer of the colorectum	383
2.4	Cancer of the liver and hepatobiliary tract	386
2.5	Cancer of the stomach	387
2.6	Cancer of the pancreas	388
2.7	Cancer of the lung	390
2.8	Cancer of the breast	394
2.9	Cancer of the uterine cervix	398
2.10	Cancer of the endometrium	399
2.11	Cancer of the ovary	402
2.12	Cancer of the prostate	403
2.13	Cancer of the kidney	405
2.14	Cancer of the urinary bladder	406
2.15	Cancers of the lymphatic and haematopoietic system	406
2.16	Other cancers	410
2.17	Parental exposure and childhood cancers	411
2.18	Polymorphisms and genetic susceptibility	412
2.19	Synthesis	446
3.	Cancer in Experimental Animals	449
3.1	Oral administration of ethanol in the drinking-water	449
3.2	Oral administration of acetaldehyde in drinking-water	452
3.3	Co-carcinogenicity studies on alcohol administered in drinking-water	453

3.4 Synthesis.....	454
4. Other Relevant Data	455
4.1 Absorption, distribution, metabolism and excretion	455
4.2 Genotoxicity.....	464
4.3 Synthesis: Mechanistic considerations.....	470
5. Evaluation	472
References	472
CHINESE-STYLE SALTED FISH.....	501
1. Exposure Data	501
1.1 Mode of production.....	501
1.2 Compounds present in salted fish.....	501
1.3 Prevalence of use of Chinese-style salted fish	502
2. Cancer in Humans.....	503
2.1 Nasopharyngeal carcinoma.....	503
2.2 Cancer of the stomach.....	505
2.3 Cancer of the oesophagus.....	506
2.4 Other cancers	506
2.5 Synthesis.....	506
3. Cancer in Experimental Animals	506
3.1 Oral administration.....	506
3.2 Synthesis.....	508
4. Other Relevant Data	508
4.1 Absorption, distribution, metabolism and excretion	508
4.2 Genetic and related effects.....	508
4.3 Mechanistic considerations	509
4.4 Synthesis.....	510
5. Evaluation	510
References	510
INDOOR EMISSIONS FROM HOUSEHOLD COMBUSTION OF COAL.....	515
1. Exposure Data	515
1.1 Constituents of coal emissions from household use of coal.....	515
1.2 Prevalence of use and exposure	518
2. Cancer in Humans.....	521
2.1 Studies in China.....	521
2.2 Studies outside China	522
2.3 Synthesis.....	523
3. Cancer in Experimental Animals	523
3.1 Coal emissions and coal soot	524
3.2 Extracts of coal soot.....	524
3.3 Veterinary epidemiology	524
3.4 Synthesis.....	528
4. Other Relevant Data	528
4.1 Inhalable particles.....	528
4.2 Polycyclic aromatic hydrocarbons.....	529

4.3 Biomarkers and mutagenicity.....	531
4.4 Synthesis.....	532
5. Evaluation.....	532
References.....	532
LIST OF ABBREVIATIONS.....	539
CUMULATIVE CROSS INDEX TO <i>IARC MONOGRAPHS</i>.....	543

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

